Simou E, Britton J, Leonardi-Bee J. Alcohol consumption and the risk of tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2018 Nov 1;22(11):1277-85.
Montserrat-Capdevila J, Godoy P, Marsal JR, Barbe F, Galvan L. Risk factors for exacerbation in chronic obstructive pulmonary disease: a prospective study. Int J Tuberc Lung Dis. 2016 Mar;20(3):389-95. doi: 10.5588/ijtld.15.0441
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Brown TM, Horblyuk RV, Grotzinger KM, Matzdorff AC, Pashos CL. Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord. 2012 Mar 1;12(1):2.
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.
Bray JW, Davis KL, Graver L, Schroeder D, Buck JA, Dilonardo J, Vandivort R. Mental health and substance abuse treatment utilization among individuals served by multiple public agencies in 3 states. J Behav Health Serv Res. 2005 Jan 1;32(3):282-93.